ArticleMolecular therapy. Methods & clinical development2019

Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs.

Elisabeth A Spronck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.